|
Public Health Service Technology Transfer Policy Board
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NCATS, NCI, NIAID, NIDA, OD/OER, OD/OIR, OD/OSP, OD/OTT
|
The purpose of the Public Health Service (PHS) Technology Transfer Policy Board (TTPB) is to serve as the principal advisory board for establishing PHS technology transfer policies and modifying existing policies, as applicable. Membership is drawn from the National Institutes of Health (NIH) as lead agency in the PHS technology transfer program, the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA).
|
|
Quantum Computing Working Group
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
NIDA
|
The Quantum Computing Working Group is a part of the National Quantum Initiative, a coordinated, multi-agency, approach to quantum information sciences, was established in 2018 “to accelerate quantum research and development for the economic and national security of the United States.” The Initiative coordinates national efforts in quantum information science (QIS) research and development and related activities across the United States Federal Government. NIH is engaged to ensure our researchers benefit from these new technologies. That means getting involved early so NIH applications can help to shape the development of new tools and algorithms.
|
|
Quantum Information Working Group
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
FIC, NCATS, NCCIH, NCI, NCMHD, NCRR, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM
|
New NIH OD stood up WG in 2023, continues in 2024. It is to continue in 2025. OSTP directed.
|
|
Racial/Ethnic Variation of HPV Type Distribution in High-Grade Cervical Precancers and Invasive Cancers in the United States
|
Research Initiative
|
CDC
|
NCI
|
The National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating in pooled anlaysis of seven U.S. studies conducted between 1997-2015 to examine HPV genotype attribution for cervical precancer and cancer by race/ethnicity.
|
|
Radiation and Chemical Defense Working Group
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, FDA, ASPR
|
NIAID, NIAMS, NIEHS
|
This group identifies scientific overlap between the chemical radiation defense missions ensures they are leveraged to advance the missions of both research areas. Goals are to understand areas of synergy in chemical and radiological insults, identify key pathways, foci of intervention, drug development. Team includes staff from across the NIH, FDA and ASPR. A scientific Zoom conference was held January 2022 and a Special Journal Issue resulting from the presentations and meeting report is nearly complete. A follow-on NOSI is in preparation to provide supplements to cross-pollinate the rad and chem research areas.
|
|
Radiation Biodosimetry Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIAID
|
This working group is focused on regulatory and scientific issues regarding technologies and devices for radiation biodosimetry. The working group assisted in drafting the new Food and Drug Administration (FDA) Center for Device and Radiological Health (CDRH) guidance for industry.
|
|
Radiation Risk and Mitigation Advisory Group
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
NCI
|
The purpose of this advisory group is to assist NASA in matters related to radiation risk assessment and countermeasures development with a focus on In Space Production (InSpa) and Space Tango (Health and Technology Manufacturing). This advisory group evaluates contract proposals submitted to NASA in response to their notice of funding opportunities regarding International Space Station utilization. It also advises the applicants on funding opportunities at NCI in areas of mutual interest.
|
|
Radiobiology Bioterrorism Research and Training Group (RABRAT)
|
Committee, Work group, Advisory group, or Task Force
|
ASPR, FDA
|
NCI, NIAID
|
This activity involves monthly meetings to discuss research initiatives, funding opportunities, training, conferences, publications, and other events and information related to preparing the US Government to respond to nuclear terrorism.
|
|
RADx Digital Health Technologies/RAPIDS
|
Resource Development
|
Not Reported
|
NCI, NIBIB, OD/DPCPSI/ODSS
|
IAA between NIH and Department of Defense, AFLCMC
|
|
Rapid Acceleration of Diagnostics Tech Program
|
Research Initiative
|
ASPR, ASPR, BARDA, CDC, CMS, FDA
|
NCI, NHLBI, NIAID, NIBIB, OD/DPCPSI/IMOD
|
To help address the COVID-19 pandemic, National Institute of Biomedical Imaging and Bioengineering (NIBIB) received $651 million (in FY2021) to support the development of new SARS-CoV-2 virus testing technologies. The Rapid Acceleration of Diagnostics (RADx®) Tech program is leveraging NIBIB's existing Point-of-Care Technologies Research Network (POCTRN) to accelerate the development, validation, and commercialization of innovative POC and home-based tests, as well as improvements to existing clinical laboratory methods. RADx Tech is supporting the full range of product development including technology validation, clinical translation, commercialization, and product distribution. RADx Tech also established the Independent Test Assessment Program (ITAP) in order to accelerate regulatory review and availability of high-quality, accurate, and reliable over-the-counter COVID-19 tests to the public.
|